RxDoctor Payments Data

Deogenes de Leon, MD

Pulmonary Disease · Orlando, FLNPI 1598744039

Payments from drug & device makers

$7,646in general payments, 2019–2025

Across 121 payments — averaging $63.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$5K
  • GSK$470
  • AstraZeneca$326
  • E.r. Squibb & Sons, L.L.C.$296
  • Insmed, Inc.$202
  • Jazz Pharmaceuticals Inc.$165
  • plus $731 from 16 others

What the payments were for

  • Speaking & faculty fees$5,03066%
  • Travel & lodging$771%
  • Food & beverage$2,39031%
  • Education$1492%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,646 in reported general payments places this provider in the 60th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$351,352
Medicare patients
935
Services billed
3,884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter191$159,720
Breo ElliptaFluticasone/Vilanterol92$48,199
TezspireTezepelumab-Ekko11$46,630
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$15,662
Arnuity ElliptaFluticasone Furoate15$5,508
SymbicortBudesonide/Formoterol Fumarate18$4,551
Albuterol Sulfate HfaAlbuterol Sulfate82$2,396
Azelastine-FluticasoneAzelastine/Fluticasone12$1,252
Montelukast Sodium66$890
Azelastine Hcl26$678
Fluticasone Propionate35$365
Pantoprazole Sodium26$300
Prednisone40$216
Azithromycin17$103
Amlodipine Besylate12$76

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$470$213,427298 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$326$66,84244 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →